Japan has a tradition of patented drug consumption and the local authorities are targeting an 80% generic penetration by 2020.
The Japanese health authorities are encouraging generic drug makers to penetrate the local market to bring down high branded prices.
Pharma14 sees this as an opportunity for European and American generic companies to act and start examining this market as a serious future customer base.
The fact that Japan is the third largest pharmaceutical market in the world speaks for itself as a great opportunity in the waiting.
Pharma14’s medicine database coverage of Japan can be an excellent tool for companies looking at this market.
Our monthly updated platform covers all registered MA’s in Japan including pricing and reimbursement information.
Pharma14’s MARKET OPPORTUNITY LOCATOR is a proprietary system that lets you know when first generic versions of molecules appear in markets on a live basis.
For example, according to our system, TADALAFIL and PREGABALIN are still not sold in a generic version in Japan but have many generic competitors in other countries.
Sample data: Tadalafil competition. USA 7 registered MA holders. Japan 1 MA holder.
Sample data: Japan Tadalafil still sold exclusively by Eli Lilly.
Sample data: Japan Pregabalin still sold exclusively by Pfizer.